GleamWall
中文EN

ONCY ONCOLYTICS BIOTECH INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1129928 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-639.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets228.7%
Debt / equity—
Current ratio0.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-145.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31 · USDFY20242024-12-31 · USD
Income statement
Revenue——
R&D expense$13.31M$15.44M
SG&A expense$15.41M$10.10M
Operating income-$28.73M-$25.54M
Pretax income-$28.68M-$22.70M
Income tax$79,000$95,000
Net income-$28.76M-$22.79M
EBITDA-$28.66M-$25.45M
EPS (basic)-0.30-0.30
EPS (diluted)-0.30-0.30
Weighted avg. shares (diluted)95.86M76.48M
Banking
Net interest income—-139,000CAD
Balance sheet
Cash & equivalents$5.20M$11.08M
Current assets$6.84M$12.44M
PP&E, net$228,000$286,000
Total assets$7.58M$13.42M
Current liabilities$6.10M$4.88M
Total liabilities$11.38M$10.12M
Shareholders' equity-$3.80M$3.30M
Shares outstanding108.02M80.02M
Cash flow statement
Operating cash flow-$20.11M-$19.88M
Capital expenditure$6,000$174,000
Free cash flow-$20.12M-$20.06M
Investing cash flow-$6,000-$174,000
Financing cash flow$14.12M$5.03M
Depreciation & amortization$70,000$87,000
Stock-based compensation$3.10M$1.98M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.